Novo Nordisk Inc. has launched the Levemir FlexTouch prefilled insulin delivery device in the United States.

Novo Nordisk, Levemir FlexTouch, prefilled insulin delivery device, prefilled insulin pen, detemir, diabetes

Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Novo Nordisk rolls out Levemir FlexTouch

June 19th, 2014

PLAINSBORO, N.J. – Novo Nordisk Inc. has launched the Levemir FlexTouch prefilled insulin delivery device in the United States.

The company said Thursday that the device marks an advancement in insulin delivery and is based on years of feedback from endocrinologists, certified diabetes educators, primary care physicians and other health care professionals, providing a new way patients with diabetes can administer their insulin.

When a dose is dialed with traditional prefilled insulin pens, the push button extends, and at larger doses this may present delivery challenges for the patient. Levemir FlexTouch is the first and only prefilled insulin delivery device with no push-button extension, according to Novo Nordisk. Because of the unique dosing mechanism of FlexTouch, the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button, the company noted.

"The features of FlexTouch were designed to help patients administer their insulin," commented Michael Shannon, M.D., chair of endocrinology and diabetes clinical advancement at Providence Health and Services. "The reduced reach and low injection force button are both advancements in improving the insulin delivery experience."

FlexTouch was approved by the Food and Drug Administration in November 2013 and the European Medicines Agency (EMA) in July 2011. The device has also launched in several countries, including the United Kingdom, Canada, Denmark, and Japan.

The Levemir FlexTouch is a prefilled insulin pen containing 300 units of insulin detemir. The pen doses in one-unit increments, from one to 80 units, and is compatible with both NovoFine and the latest NovoTwist needles. An audible and tactile "click" confirms attachment of the needle.

"At Novo Nordisk, we are committed to developing devices to help the more than 29 million people with diabetes in the United States," stated Camille Lee, senior vice president of diabetes Marketing at Novo Nordisk. "Levemir FlexTouch was designed to address the needs of these individuals, providing patients and their health care professionals with a new tool to help improve the way they manage their diabetes."